Chemical Component Summary

Name MONTELUKAST
Identifiers 2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]ethanoic acid
Formula C35 H36 Cl N O3 S
Molecular Weight 586.18 g/mol
Type non-polymer
Isomeric SMILES CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1
InChI InChI=1S/C35H36ClNO3S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/b15-10+/t32-/m1/s1
InChI Key UCHDWCPVSPXUMX-TZIWLTJVSA-N

Chemical Details

Formal Charge 0
Atom Count 77
Chiral Atom Count 1
Chiral Atoms CBM
Bond Count 81
Aromatic Bond Count 23

Drug Info: DrugBank

DrugBank ID DB00471   (Stereoisomeric match)
Name Montelukast
Groups approved
Description Montelukast is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. It is usually administered orally. Montelukast blocks the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it. This reduces the bronchoconstriction otherwise caused by the leukotriene, and results in less inflammation. Because of its method of operation, it is not useful for the treatment of acute asthma attacks. Again because of its very specific locus of operation, it does not interact with other allergy medications such as theophylline. Montelukast is marketed in United States and many other countries by Merck & Co. with the brand name Singulair®. It is available as oral tablets, chewable tablets, and oral granules. In India and other countries, it is also marketed under the brand name Montair®, produced by Indian company Cipla.
Synonyms
  • (R-(e))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid
  • 1-[[[(1 R)-1-[3-[(1e)-2-(7-chloro-2-Quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetic acid
  • Montelukast
  • Montélukast
  • Montelukastum
Salts Montelukast sodium
Brand Names
  • Accel-montelukast Sodium Tablets
  • Ach-montelukast
  • Apo-montelukast
  • Auro-montelukast
  • Auro-montelukast Chewable Tablet
  • Bio-montelukast
  • Dom-montelukast
  • Dom-montelukast Fc
  • Ipg-montelukast
  • Jamp-montelukast
  • Mar-montelukast
  • Mint-montelukast
  • Montelukast
  • Montelukast Sodium
  • Montelukast Sodium Chewable
  • Montelukast Sodium Tablets
  • Mylan-montelukast
  • Ntp-montelukast
  • PMS-montelukast
  • PMS-montelukast Fc
  • Pendo-montelukast
  • Pendo-montelukast Fc
  • Priva-montelukast Fc
  • Q-montelukast
  • Ran-montelukast
  • Ratio-montelukast
  • Riva-montelukast
  • Riva-montelukast Fc
  • Sandoz Montelukast
  • Sandoz Montelukast Granules
  • Sandoz Montelukast Tablet
  • Singulair
  • Teva-montelukast
  • Uni-montelukast
  • Van-montelukast
  • Lukotas
  • Molly
  • Monocast
  • Monteflo
  • Montelo-10
  • Montene
  • Respaire
  • Surfair
  • Telumantes
  • Ventek
  • Ventilar
  • Xalar
  • Zespira
[more]
Affected Organism Humans and other mammals
Indication For the treatment of asthma
Pharmacology Montelukast, like zafirlukast, is a leukotriene receptor antagonist used as an alternative to anti-inflammatory medications in the management and chronic treatment of asthma and exercise-induced bronchospasm (EIB). Unlike zafirlukast, montelukast does not inhibit CYP2C9 or CYP3A4 and is, therefore, not expected to affect the hepatic clearance of drugs metabolized by these enzymes.
Mechanism of action Montelukast selectively antagonizes leukotriene D4 (LTD4) at the cysteinyl leukotriene receptor, CysLT1, in the human airway. Montelukast inhibits the actions of LTD4 at the CysLT1 receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus.
Route of administration oral
Categories Anti-Arrhythmia Agents
ATC-Code R03DC03
AHFS-Code 48:10.24
CAS number 158966-92-8
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID: 21059682